Is IO Monotherapy the New Standard of Care in Advanced NSCLC? Is IO Monotherapy the New Standard of Care in Advanced NSCLC?
Merck has released provocative but limited findings from the KEYNOTE-042 trial that indicate better outcomes for first-line pembrolizumab vs standard chemotherapy in advanced non-small cell lung cancer (NSCLC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Merck | Non-Small Cell Lung Cancer